Physician profile
John M Wat
NPI 1841223096
$3,239.79
in general payments reported to CMS, 2019-2025
20 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $70.82 · 2021: $482 · 2022: $630 · 2023: $474 · 2024: $617 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $720.15 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $550.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $398.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $228.85 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $182.18 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $167.66 | 2019-2022 | |
| Amgen INC. | $163.28 | 2021-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $157.53 | 2022-2024 | Gardasil 9, Gardasil, Verquvo |
| Novartis Pharmaceuticals Corporation | $130.79 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.74 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Boston Scientific Corporation | $108.27 | 2019 | |
| Hydrofera LLC | $103.03 | 2021 | |
| Pfizer INC. | $48.04 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $34.29 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $31.14 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $27.41 | 2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.51 | 2025 | Caplyta |
| Abbvie INC. | $21.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.34 | 2023 | Cuvitru |
| Bayer Healthcare Pharmaceuticals INC. | $14.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.